EU gives nod to joint venture
In what could be an example of how European regulators like to see things done, the European Union has approved a joint venture between Europe-based companies Draegerwerk and Siemens Medical Solutions. Draeger will contribute its entire medical division
In what could be an example of how European regulators like to see things done, the European Union has approved a joint venture between Europe-based companies Draegerwerk and Siemens Medical Solutions. Draeger will contribute its entire medical division to the joint venture, which will address the acute hospital care marketplace. Siemens will contribute its patient monitoring systems. The result will be called Draeger Medical-A Draeger and Siemens Company. Ownership will be split 65% Draeger and 35% Siemens.
Under the deal, Siemens will sell its Life Support Systems unit, composed of anesthesia and ventilation devices, to a third party. The joint venture will continue to supply open data interfaces to enable integration of its products and devices with those of other companies. The joint venture's sales organization will work closely with that of Siemens, especially in developing cross-departmental solutions for hospitals and supporting key accounts. In cooperation with Siemens and through the use of the Siemens software platforms syngo and Soarian as basic architecture, the joint venture will develop, produce, and market critical care IT solutions for optional integration into more comprehensive healthcare solutions, according to Siemens.
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
